[go: up one dir, main page]

CY1115937T1 - Εισπνεομενο φαρμακο που περιεχει αμορφο βρωμιουχο τιοτροπιο - Google Patents

Εισπνεομενο φαρμακο που περιεχει αμορφο βρωμιουχο τιοτροπιο

Info

Publication number
CY1115937T1
CY1115937T1 CY20141101038T CY141101038T CY1115937T1 CY 1115937 T1 CY1115937 T1 CY 1115937T1 CY 20141101038 T CY20141101038 T CY 20141101038T CY 141101038 T CY141101038 T CY 141101038T CY 1115937 T1 CY1115937 T1 CY 1115937T1
Authority
CY
Cyprus
Prior art keywords
bromide
tiotropio
amorphone
inhalated
medicine contained
Prior art date
Application number
CY20141101038T
Other languages
English (en)
Inventor
Xian-Ming Zeng
Original Assignee
Norton Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38566522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115937(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norton Healthcare Limited filed Critical Norton Healthcare Limited
Publication of CY1115937T1 publication Critical patent/CY1115937T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αυτή αφορά σε ένα εισπνεόμενο φάρμακο και ιδιαιτέρως σε μία νέα στερεάς-κατάστασης μορφή βρωμιούχου τιοτροπίου, δηλαδή, στερεά άμορφα σωματίδια που περιλαμβάνουν πλήρες μίγμα βρωμιούχου τιοτροπίου μαζί με φαρμακευτικώς αποδεκτό συν-στερεό που έχει θερμοκρασία μετάπτωσης υάλου τουλάχιστον -5ο DEG C, όπως σάκχαρο ή/και παράγωγο σακχάρου.
CY20141101038T 2007-07-09 2014-12-12 Εισπνεομενο φαρμακο που περιεχει αμορφο βρωμιουχο τιοτροπιο CY1115937T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95882307P 2007-07-09 2007-07-09
GBGB0716026.0A GB0716026D0 (en) 2007-08-16 2007-08-16 An inhalable medicament
EP08775842.1A EP2175838B2 (en) 2007-07-09 2008-07-03 An inhalable medicament containinig amorphous tiotropium bromide

Publications (1)

Publication Number Publication Date
CY1115937T1 true CY1115937T1 (el) 2017-01-25

Family

ID=38566522

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101038T CY1115937T1 (el) 2007-07-09 2014-12-12 Εισπνεομενο φαρμακο που περιεχει αμορφο βρωμιουχο τιοτροπιο

Country Status (20)

Country Link
US (3) US8759369B2 (el)
EP (1) EP2175838B2 (el)
JP (1) JP5552049B2 (el)
KR (1) KR101542632B1 (el)
CN (1) CN101754749B (el)
BR (1) BRPI0813564A2 (el)
CA (1) CA2692606C (el)
CY (1) CY1115937T1 (el)
DK (1) DK2175838T4 (el)
EA (2) EA020968B1 (el)
ES (1) ES2526647T5 (el)
GB (1) GB0716026D0 (el)
HR (1) HRP20141175T4 (el)
IL (2) IL203180A (el)
MX (1) MX2010000315A (el)
PL (1) PL2175838T5 (el)
PT (1) PT2175838E (el)
RS (1) RS53784B2 (el)
SI (1) SI2175838T2 (el)
WO (1) WO2009007687A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
CN103110584A (zh) * 2013-01-29 2013-05-22 青岛大学 一种噻托溴铵粉雾剂及其制备方法
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
EP2913332A1 (en) 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
GB201409603D0 (en) * 2014-05-30 2014-07-16 Teva Pharmaceuticals Europ B V An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
KR101728116B1 (ko) * 2015-11-03 2017-04-18 한미약품 주식회사 티오트로피움 또는 이의 약학적으로 허용가능한 염을 함유하는 흡입용 건조분말 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB9027234D0 (en) * 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
WO1993011745A1 (en) 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
ES2192866T3 (es) 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
US7022311B1 (en) 1999-10-12 2006-04-04 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
PT1292281E (pt) * 2000-10-12 2004-11-30 Boehringer Ingelheim Pharma Novos pos para inalacao contendo tiotropio
WO2002030928A1 (de) * 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
CN100586948C (zh) 2001-06-22 2010-02-03 贝林格尔英格海姆法玛两合公司 结晶性抗胆碱能药,其制备方法及其在药物制备中的用途
US6608055B2 (en) * 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US7309707B2 (en) * 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
CA2576410A1 (en) * 2003-09-18 2006-03-31 Norton Healthcare Ltd. Particles
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
KR101313904B1 (ko) 2003-11-03 2013-09-30 베링거 인겔하임 인터내셔날 게엠베하 항콜린성 효과를 지닌 신규한 무수 결정
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
CN1270709C (zh) * 2004-01-19 2006-08-23 复旦大学 一种噻托溴铵吸入粉雾剂及其制备方法
WO2005086915A2 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CN1593414A (zh) * 2004-07-02 2005-03-16 上海华拓医药科技发展有限公司 一种噻托溴铵胶囊型吸入粉雾剂及其制备方法
JP5227790B2 (ja) * 2005-05-02 2013-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
BRPI0611091A2 (pt) * 2005-05-02 2010-08-03 Boehringer Ingelheim Int formas cristalinas de brometo de tiotrópico
RU2418796C2 (ru) 2005-06-15 2011-05-20 Берингер Ингельхайм Интернациональ Гмбх Способ получения новых солей тиотропия
ATE552256T1 (de) * 2005-12-19 2012-04-15 Sicor Inc Neuartige form von tiotropium-bromid und herstellungsverfahren dafür
EP1923393A1 (en) 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea

Also Published As

Publication number Publication date
CA2692606C (en) 2014-04-01
EP2175838B1 (en) 2014-10-08
RS53784B1 (en) 2015-06-30
GB0716026D0 (en) 2007-09-26
JP5552049B2 (ja) 2014-07-16
EP2175838A2 (en) 2010-04-21
SI2175838T1 (sl) 2015-03-31
MX2010000315A (es) 2010-03-17
EA020968B1 (ru) 2015-03-31
EA201500111A1 (ru) 2015-10-30
DK2175838T4 (en) 2017-08-28
PL2175838T3 (pl) 2015-05-29
HRP20141175T4 (hr) 2017-09-22
PL2175838T5 (pl) 2018-03-30
ES2526647T5 (es) 2017-10-10
CN101754749A (zh) 2010-06-23
US20140127304A1 (en) 2014-05-08
IL203180A (en) 2015-01-29
WO2009007687A3 (en) 2009-06-04
JP2010533156A (ja) 2010-10-21
DK2175838T3 (en) 2015-01-05
WO2009007687A2 (en) 2009-01-15
US8759369B2 (en) 2014-06-24
BRPI0813564A2 (pt) 2015-08-25
CA2692606A1 (en) 2009-01-15
EP2175838B2 (en) 2017-06-07
KR101542632B1 (ko) 2015-08-06
HRP20141175T1 (hr) 2015-03-13
ES2526647T3 (es) 2015-01-14
EA030829B1 (ru) 2018-10-31
IL236360A0 (en) 2015-09-24
RS53784B2 (sr) 2018-07-31
EA201070115A1 (ru) 2010-06-30
PT2175838E (pt) 2015-01-14
SI2175838T2 (sl) 2017-09-29
CN101754749B (zh) 2016-04-13
US20150150808A1 (en) 2015-06-04
US20100326437A1 (en) 2010-12-30
KR20100045999A (ko) 2010-05-04

Similar Documents

Publication Publication Date Title
CY1115937T1 (el) Εισπνεομενο φαρμακο που περιεχει αμορφο βρωμιουχο τιοτροπιο
CY1123764T1 (el) Τετραϋδροβιοπτερινη για θεραπεια καταστασεων που σχετιζονται με αυξημενα επιπεδα φαινυλαλανινης
CY1118221T1 (el) Εκλεκτικοι συνδετες συνδεσης οψινης, συνθεσεις και μεθοδοι χρησης
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1118099T1 (el) Δισκια οξεικης ουλιπρισταλης
CY1113136T1 (el) Αντιμετωπιση των διαταραχων των χονδρων με ton fgf-18
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1113315T1 (el) Ιμιδαζολοκαρβοξαμιδια
CY1115844T1 (el) Μακροκυκλικοι αναστολεις της πρωτεασης σερινης της ηπατιτιδας c
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
CY1114272T1 (el) Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
EP2395834A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SODIUM NITRITE
CY1111169T1 (el) Βενζοϊμιδαζολ-2-υλ πυριμιδινες και πυραζινες ως τροποποιητες του υποδοχεα ισταμινης h4
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
UY31053A1 (es) Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1112643T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη